China Healthwise Holdings (0348) AI Stock Analysis

• Market Cap: HK$100.16M
• Dividend Yield: N/A
• Average Volume (3M): 735.98K
• Price to Earnings (P/E): 19.0
• Beta (1Y): 1.12
• Revenue Growth: -17.97%
• EPS Growth: 92.26%
• Country: HK
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): <0.01
• Shares Outstanding: 770,480,830
• 10 Day Avg. Volume: 624,920
• 30 Day Avg. Volume: 735,980
• PEG Ratio: 0.04
• Price to Book (P/B): -6.50
• Price to Sales (P/S): 1.05
• P/FCF Ratio: 38.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$0.13 ▼(-7.86% Downside)
• Action: Downgraded Date: 12/31/25
• Date: Action: Downgraded 12/31/25

The score is driven primarily by very weak financial performance (declining revenue, ongoing losses, negative equity, and zero operating/free cash flow in 2024). Technical indicators also lean bearish with the price below key moving averages and negative MACD. Valuation does not offset these risks because losses drive a negative P/E and there is no dividend yield support.

Positive Factors

Market Position

China Healthwise's focus on holistic health solutions positions it well in the growing market for alternative and complementary healthcare, potentially increasing its customer base and revenue streams.

Revenue Streams

Diverse revenue streams from health supplements, wellness products, and TCM services provide a buffer against market fluctuations and support long-term growth potential.

Industry Trends

The increasing consumer preference for preventive healthcare and natural remedies aligns with China Healthwise's offerings, supporting sustained demand and potential market expansion.

Negative Factors

Revenue Decline

Consistent revenue decline over recent years suggests challenges in maintaining market share and competitiveness, potentially impacting long-term financial health.

Negative Equity

Negative equity indicates potential solvency issues, raising concerns about the company's ability to meet long-term obligations and sustain operations.

Cash Flow Issues

Zero operating cash flow in 2024 highlights cash management issues, limiting the company's ability to invest in growth and manage financial obligations.

China Healthwise Holdings Business Overview & Revenue Model

Company Description

China Healthwise Holdings Limited, an investment holding company, sells Chinese health products in Hong Kong. It operates through Chinese Health Products, Money Lending Business, and Investment in Financial Instruments segments. The company sells Chinese and other pharmaceutical products, health products, ginseng, and dried seafood products to wholesalers and retailers. It also sells Chinese health products online. The company was formerly known as Haier Healthwise Holdings Limited and changed its name to China Healthwise Holdings Limited in January 2017. China Healthwise Holdings Limited is headquartered in Central, Hong Kong.

How the Company Makes Money

China Healthwise generates revenue through multiple streams, primarily from the sale of health supplements and wellness products, as well as offering traditional Chinese medicine services. The company capitalizes on its established brand reputation in the health sector to attract customers seeking alternative and complementary healthcare solutions. Additionally, China Healthwise may engage in partnerships with health practitioners and wellness centers, enhancing its distribution channels and customer reach, which further contributes to its earnings. The growing trend towards preventive healthcare and natural remedies plays a significant role in driving the company's sales and overall revenue growth.

China Healthwise Holdings Financial Statement Overview

Summary

Very weak fundamentals: revenue has declined from 2021–2024, profitability remains negative with deteriorating margins, equity is negative (liabilities exceed assets), and operating/free cash flow fell to zero in 2024—raising financial stability and solvency risk.

Income Statement

The company has experienced consistent revenue declines from 2021 to 2024, with a significant drop in net income from -$103 million in 2021 to -$40 million in 2024. Gross profit margin has fallen from 53.5% in 2021 to 30.8% in 2024. The net profit margin and EBIT margin are both negative, indicating ongoing operational challenges.

Balance Sheet

The company has a negative stockholders' equity of -$18.38 million in 2024, indicating potential solvency issues. The debt-to-equity ratio is not applicable due to negative equity, but the overall liabilities exceed assets. The equity ratio is negative, reflecting a concerning balance sheet situation.

Cash Flow

Operating cash flow has significantly declined from $42 million in 2021 to $0 in 2024. Free cash flow was positive in 2023 but dropped to zero in 2024, indicating cash flow management issues. There is no free cash flow growth, and the operating cash flow to net income ratio is unavailable due to zero operating cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	103.70M	113.58M	146.32M	142.06M	170.08M	137.85M
Gross Profit	34.99M	35.00M	60.29M	53.27M	90.99M	61.06M
EBITDA	-9.22M	-20.07M	-117.45M	-45.80M	-89.97M	-45.33M
Net Income	-10.20M	-40.28M	-134.56M	-54.27M	-103.05M	-71.45M
Balance Sheet
Total Assets	110.90M	122.05M	149.67M	287.66M	314.10M	434.28M
Cash, Cash Equivalents and Short-Term Investments	47.17M	44.72M	54.28M	73.02M	96.91M	139.92M
Total Debt	107.93M	103.74M	108.90M	109.90M	90.86M	113.81M
Total Liabilities	127.86M	140.43M	145.27M	149.01M	121.03M	137.99M
Stockholders Equity	-16.96M	-18.38M	4.40M	138.65M	193.06M	296.29M
Cash Flow
Free Cash Flow	5.39M	3.12M	14.30M	-28.97M	41.72M	7.47M
Operating Cash Flow	5.59M	3.38M	14.49M	-28.34M	42.08M	11.99M
Investing Cash Flow	-200.00K	-257.00K	-191.00K	-631.00K	-360.00K	1.50M
Financing Cash Flow	-6.47M	-7.84M	-17.04M	5.95M	-36.36M	-25.75M

China Healthwise Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0348, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.60 is Neutral, neither overbought nor oversold. The STOCH value of 33.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0348.

China Healthwise Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2211	59 Neutral	HK$64.12M	-3.29	-7.71%	―	-34.73%	-4642.86%
1110	56 Neutral	HK$309.31M	-13.32	0.86%	5.87%	-10.78%	-82.81%
3390	53 Neutral	HK$268.20M	-9.36	-4.89%	28.00%	-1.68%	-111.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2700	51 Neutral	HK$376.14M	-21.76	-7.37%	―	11.32%	62.61%
0399	48 Neutral	HK$452.13M	-1.59	―	―	―	―
0348	39 Underperform	HK$100.16M	19.02	―	―	-17.97%	92.26%

China Healthwise Holdings Corporate Events

China Healthwise Subsidiary Hit by Forced Sale of Yunfeng Financial Shares to Clear Margin Debt

China Healthwise Holdings has disclosed that its indirect wholly owned subsidiary Future Empire Limited was subject to a forced sale of 2,646,000 shares in Yunfeng Financial Group, generating about HK$9.2 million before costs. The disposal, triggered under margin financing terms by the securities broker to clear overdue balances, fully settled Future Empire’s outstanding obligations to the broker, while the subsidiary retains 4,316,000 Yunfeng Financial Group shares with the same firm; the company has urged shareholders and potential investors to exercise caution when trading its stock, underscoring the financial-management sensitivity around leveraged securities positions.

The most recent analyst rating on (HK:0348) stock is a Sell with a HK$0.13 price target. To see the full list of analyst forecasts on China Healthwise Holdings stock, see the HK:0348 Stock Forecast page.